GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Akumin Inc (OTCPK:AKUMQ) » Definitions » EV-to-EBITDA

Akumin (Akumin) EV-to-EBITDA : -47.77 (As of May. 03, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akumin EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Akumin's enterprise value is $1,513.3 Mil. Akumin's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-31.7 Mil. Therefore, Akumin's EV-to-EBITDA for today is -47.77.

The historical rank and industry rank for Akumin's EV-to-EBITDA or its related term are showing as below:

AKUMQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -324.05   Med: 28.12   Max: 116.41
Current: -47.77

During the past 8 years, the highest EV-to-EBITDA of Akumin was 116.41. The lowest was -324.05. And the median was 28.12.

AKUMQ's EV-to-EBITDA is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 16.35 vs AKUMQ: -47.77

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), Akumin's stock price is $0.375. Akumin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.820. Therefore, Akumin's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Akumin EV-to-EBITDA Historical Data

The historical data trend for Akumin's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akumin EV-to-EBITDA Chart

Akumin Annual Data
Trend Sep15 Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial 13.58 35.40 43.64 41.72 22.92

Akumin Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.19 22.92 23.74 116.19 -52.51

Competitive Comparison of Akumin's EV-to-EBITDA

For the Diagnostics & Research subindustry, Akumin's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akumin's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Akumin's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Akumin's EV-to-EBITDA falls into.



Akumin EV-to-EBITDA Calculation

Akumin's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1513.258/-31.679
=-47.77

Akumin's current Enterprise Value is $1,513.3 Mil.
Akumin's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akumin  (OTCPK:AKUMQ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Akumin's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.375/-2.820
=At Loss

Akumin's share price for today is $0.375.
Akumin's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.820.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Akumin EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Akumin's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Akumin (Akumin) Business Description

Traded in Other Exchanges
Address
8300 West Sunrise Boulevard, Plantation, FL, USA, 33322
Akumin Inc is a Canada-based company that provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company operates in Florida, Pennsylvania, Delaware, Texas, Illinois, and Kansas. It offers physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, minimizing the cost and amount of care for patients. The company's imaging procedures include MRI, CT, positron emission tomography, ultrasound, X-ray, mammography, and other diagnostic or interventional radiology procedures. It operates in two reportable business segments: radiology and oncology. The radiology segment acconts for majority revenue.
Executives
Ronald J. Bienias officer: Chief Restructuring Officer C/O AKUMIN INC.,, 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
Stonepeak Gp Investors Holdings Manager Llc 10 percent owner, other: See Remarks 55 HUDSON YARDS, 550 WEST 34TH STREET, 48TH FLOOR, NEW YORK NY 10001
Stonepeak Gp Investors Upper Holdings Lp 10 percent owner, other: See Remarks 55 HUDSON YARDS, 550 WEST 34TH STREET, 48TH FLOOR, NEW YORK NY 10001
Stonepeak Gp Investors Holdings Lp 10 percent owner, other: See Remarks 55 HUDSON YARDS, 550 WEST 34TH STREET, 48TH FLOOR, NEW YORK NY 10001
Krishna Kumar officer: See remarks C/O AKUMIN INC., 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
Lawrence Ross Sinclair director 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
R. David Kretschmer officer: See Remarks 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Murray Lee director 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
Scw Capital Management, Lp 10 percent owner 3131 TURTLE CREEK BLVD., SUITE 302, DALLAS TX 75219
Trinity Investment Group, Llc 10 percent owner 3131 TURTLE CREEK BLVD., #302, DALLAS TX 75219
Robert N. Cathey 10 percent owner 3131 TURTLE CREEK BLVD., #302, DALLAS TX 75219
John R. Wagner 10 percent owner 3838 OAK LAWN AVE., SUITE 450, DALLAS TX 75219
Paul Nelis officer: Chief Information Officer 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
Haichen Huang director 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
Matt Cameron officer: See Remarks 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322

Akumin (Akumin) Headlines

From GuruFocus

Akumin Announces First Quarter 2022 Results

By PRNewswire PRNewswire 06-09-2022

Akumin Announces First Quarter 2022 Results

By PRNewswire PRNewswire 05-30-2022

Akumin Announces Third Quarter 2022 Results

By PRNewswire PRNewswire 11-09-2022

Akumin appoints President and Chief Operating Officer

By PRNewswire PRNewswire 06-12-2023

Akumin Announces Change of Auditor

By PRNewswire 08-09-2023

Akumin Announces First Quarter 2022 Results

By PRNewswire PRNewswire 07-09-2022

Akumin Announces Second Quarter 2022 Results

By PRNewswire PRNewswire 08-09-2022